- Home
- ICLR
ICLR
ICON plc
as 07-26-2024 4:00pm EST
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
| Founded: | 1990 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 26.5B | IPO Year: | 1998 |
| Target Price: | $353.11 | AVG Volume (30 days): | 822.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.59 | EPS Growth: | 39.00 |
| 52 Week Low/High: | $221.20 - $347.72 | Next Earning Date: | 07-24-2024 |
| Revenue: | $8,331,892,000 | Revenue Growth: | 5.42% |
| Revenue Growth (this year): | 8.54% | Revenue Growth (next year): | 7.62% |
Latest ICON plc News
ICLR Breaking Stock News: Dive into ICLR Ticker-Specific Updates for Smart Investing
Zacks
10 hours ago
3 Medical Services Industry Stocks to Buy as Healthcare Wage Increases
Zacks
10 hours ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Zacks
11 hours ago
ICON (ICLR) Q2 Earnings Surpass Estimates, Margins Expand
Simply Wall St.
11 hours ago
ICON Second Quarter 2024 Earnings: Misses Expectations
Morningstar Research
a day ago
Analyst Report: ICON Public Limited Company
Zacks
2 days ago
Icon PLC (ICLR) Q2 Earnings Surpass Estimates
Business Wire
2 days ago
ICON Reports Second Quarter 2024 Results
Business Wire
3 days ago
ICON announces results of Annual General Meeting and changes to the Board of Directors
Compare ICLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ICLR ICON plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.